Preview Mode Links will not work in preview mode


Jan 4, 2019

Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments.

  • Intro :10
  • Background on Dr. Furie :16
  • The interview :56
    • What advancements in the pathophysiology of lupus are you most excited about? 1:10
    • The interferon story 1:23
      • The interferon story is not finished yet 7:18
      • Dendritic cells in lupus patients 7:41
      • What is “interferon signature?” 8:07
      • Do we see different clinical phenotype in patients with high interferon signature? 9:38
    • What’s your opinion on the role of B cells? 10:07
      • Any other pathophysiology mechanisms being used to target B cells? 13:15
    • Are we stretched thin in terms of number of lupus patients in trials? 15:21
      • How would designating lupus as an orphan disease change the way it’s investigated? 16:40
      • What is your main concern regarding study design? 17:37
    • Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26
    • What’s the expense of cytokine profiling? 22:40
    • What excites you the most about the future of lupus research? 23:21
  • Thank you, Dr. Furie 24:41
  • Recap 24:43
  • Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31

We’d love to hear from you! Send your comments/questions to And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum.

This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.